{"id":726759,"date":"2023-01-30T08:22:03","date_gmt":"2023-01-30T13:22:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/"},"modified":"2023-01-30T08:22:03","modified_gmt":"2023-01-30T13:22:03","slug":"vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/","title":{"rendered":"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Dr. Pelletier joins leadership team to continue the advancement of Vaccitech\u2019s <\/em><br \/>\n          <em>diverse clinical pipeline and partnerships, bringing more than 15 years\u2019 experience in pharmaceuticals and academia in immunology and infectious diseases<\/em><br \/>\n          \n        <\/li>\n<li style=\"margin-top:12pt;margin-bottom:8pt;text-align:left\">\n          <em>Former CSO, Dr. Tom Evans to continue supporting company as a consultant<\/em>\n        <\/li>\n<\/ul>\n<p>OXFORD, United Kingdom, Jan.  30, 2023  (GLOBE NEWSWIRE) &#8212; Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer today announced the appointment of Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer (CSO).<\/p>\n<p>\u201cWe are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,\u201d said Chief Executive Officer, Bill Enright. \u201cDr. Pelletier\u2019s wealth of experience in drug discovery and development, as well as her ability to establish and maintain lasting collaborations within the industry, will propel the advancement of our growing pipeline and support our mission to deliver first-in-class therapies for devastating diseases that pose significant public health risks.\u201d<\/p>\n<p>Dr. Pelletier is stepping into the role formerly held by Tom Evans, Ph.D., who is retiring but will remain involved as a scientific consultant to the company.<\/p>\n<p>\u201cFor the past six years, Tom has been integral in elevating Vaccitech\u2019s profile and pipeline to serve a global patient community. We extend our tremendous gratitude for his leadership, passion, and drive,\u201d added Mr. Enright. \u201cWhile he is stepping back as CSO, he will continue to advise on our scientific efforts.\u201d<\/p>\n<p>Dr. Pelletier will lead Vaccitech\u2019s scientific teams in all phases of drug discovery and platform development, as well as build and oversee the strategic technical direction of the company.<\/p>\n<p>Dr. Pelletier brings extensive experience to Vaccitech in the areas of immunology, inflammation and infectious diseases. She joins Vaccitech from the Novartis Institutes for Biomedical Research and prior to that Roche Pharma Research &amp; Early Development, where she served as Project Leader in the fields of autoimmunity, inflammation and infectious diseases. At Novartis, Dr. Pelletier was a discovery leader in a fast-track, multi-indication early clinical program on tolerance induction, and was responsible for maintaining accountability in building solid preclinical packages, biomarker strategies, and translational plans for disease focus and indication expansion. Prior to her role at Novartis, Dr. Pelletier was responsible for several preclinical and clinical projects in all phases of development to restore immune balance in autoimmunity and chronic infectious diseases, and was a key contributor to advancing immune modulation strategies for chronic Hepatitis B and respiratory infections.<\/p>\n<p>\u201cIt\u2019s an exciting time to be joining Vaccitech,\u201d said Dr. Pelletier. \u201cI look forward to supporting the work underway and generating new strategies that will help the company achieve its goal of advancing a deep clinical-stage pipeline of therapies for life-threatening diseases that currently have limited treatment options, where its T cell therapeutic candidates are ideally suited for restoring effective, balanced, antigen-targeted immune responses.\u201d<\/p>\n<p>In addition to her experience with Novartis and Roche, Dr. Pelletier also served as a Senior Scientist at Merck-Serono in Geneva, Switzerland, and as a postdoctoral fellow at the Scripps Research Institute in La Jolla, California.<\/p>\n<p>Dr. Pelletier holds a Ph.D. in immunology from Claude Bernard University, ENS-Lyon, in Lyon, France and a Master of Science in Genetics and Immunology from ENS-Lyon.<\/p>\n<p>\n        <strong>About Vaccitech<\/strong>\n      <\/p>\n<p>Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics designed to utilize the power of the immune system to treat and cure chronic infectious diseases, autoimmune diseases, and cancer. The company stands apart through a proprietary, multi-platform approach that has shown the ability to induce higher magnitudes of T cells compared with other technologies. Vaccitech is uniquely positioned to address the needs of large, underserved patient populations through a diverse clinical-stage pipeline of investigational therapies targeting life-threatening diseases that pose significant public health risk and have limited treatment options. The company\u2019s lead product candidates include VTP-300, an immunotherapy candidate designed as a component of a potential functional cure for chronic hepatitis B viral (HBV) infection; VTP-200, a non-invasive, early-stage investigational treatment for persistent, high-risk human papillomavirus (HPV); VTP-850, a novel T cell investigational therapy for prostate cancer; and VTP-1000, a preclinical T cell therapeutic candidate for immune tolerance in celiac disease. Vaccitech has proven drug development and scientific expertise in the field of immunization, co-inventing a COVID-19 vaccine with the University of Oxford, which is now approved and exclusively licensed worldwide to AstraZeneca. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZaQ0rG7Kt1tAFivnmXDEi6xcsIib9Ae8IO0dpPv1k0ITXW9CSqgJr8iIW3T7K0PrHCV6Bdy1g-uA3485fZSlysZq6I5m7mHgAYIKZW_8b50=\" rel=\"nofollow noopener\" target=\"_blank\">www.vaccitech.co.uk<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>IR contacts:<\/strong>\n          <\/td>\n<td style=\"max-width:70%;width:70%;min-width:70%;text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%;text-align: left;vertical-align: middle;vertical-align: top\">Christopher M. Calabrese\u202f<br \/>Managing Director\u202f <br \/>LifeSci Advisors <br \/>917-680-5608 <br \/><a href=\"mailto:ccalabrese@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">ccalabrese@lifesciadvisors.com<\/a><\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%;text-align: left;vertical-align: middle;vertical-align: top\">Kevin Gardner <br \/>Managing Director <br \/>LifeSci Advisors <br \/>617-283-2856 <br \/><a href=\"mailto:kgardner@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Media contact:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">Mike Beyer<br \/>Sam Brown, Inc.<br \/>312-961-2502<br \/><a href=\"mailto:mikebeyer@sambrown.com\" rel=\"nofollow noopener\" target=\"_blank\">mikebeyer@sambrown.com<\/a><\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Company contact:<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">Jonothan Blackbourn<br \/>IR &amp; PR Manager<br \/>Vaccitech<br \/><a href=\"mailto:IR@vaccitech.co.uk\" rel=\"nofollow noopener\" target=\"_blank\">IR@vaccitech.co.uk<\/a><\/td>\n<\/tr>\n<\/table>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6F9K0RyERBCF0PQH-C5CAasWuwooI5tlq2NAdnRScNh3vp_Lx16j9qNUyUM3PmoKmK8mLEpdr3f66elTtNWrRqKBNV4YbBl6sPeCHKW7D0i_QTS7OH3G9gQTkQVZCajtYFn-KGoTyvaMFkc9QZpARy0aiW9hZHOmlEVouToXzF-z1XM-tQsD58wW_HwYVDdwLfbcZ3zpjADL5Hh7C62qEWN2H5IQcThd29oONzBBibPqQ9C8i5bQzHiFnk-kNlqNWqxgQUm1Ttegv5kDyQ8HSg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/cf3e4392-f7ad-4b2f-b5ad-cee464ee7fb4<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjYxYzE3M2UtMGJlYS00MzlmLTlkM2ItZGE4YmI2OWZkZjUyLTEyMTYzNjE=\/tiny\/Vaccitech-UK-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Pelletier joins leadership team to continue the advancement of Vaccitech\u2019s diverse clinical pipeline and partnerships, bringing more than 15 years\u2019 experience in pharmaceuticals and academia in immunology and infectious diseases Former CSO, Dr. Tom Evans to continue supporting company as a consultant OXFORD, United Kingdom, Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer today announced the appointment of Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer (CSO). \u201cWe are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,\u201d said &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726759","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dr. Pelletier joins leadership team to continue the advancement of Vaccitech\u2019s diverse clinical pipeline and partnerships, bringing more than 15 years\u2019 experience in pharmaceuticals and academia in immunology and infectious diseases Former CSO, Dr. Tom Evans to continue supporting company as a consultant OXFORD, United Kingdom, Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer today announced the appointment of Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer (CSO). \u201cWe are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,\u201d said &hellip; Continue reading &quot;Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T13:22:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer\",\"datePublished\":\"2023-01-30T13:22:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/\"},\"wordCount\":834,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/\",\"name\":\"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=\",\"datePublished\":\"2023-01-30T13:22:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/","og_locale":"en_US","og_type":"article","og_title":"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer - Market Newsdesk","og_description":"Dr. Pelletier joins leadership team to continue the advancement of Vaccitech\u2019s diverse clinical pipeline and partnerships, bringing more than 15 years\u2019 experience in pharmaceuticals and academia in immunology and infectious diseases Former CSO, Dr. Tom Evans to continue supporting company as a consultant OXFORD, United Kingdom, Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer today announced the appointment of Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer (CSO). \u201cWe are pleased to welcome Dr. Pelletier to Vaccitech at the start of 2023, a year in which we anticipate several important clinical milestones,\u201d said &hellip; Continue reading \"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-30T13:22:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer","datePublished":"2023-01-30T13:22:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/"},"wordCount":834,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/","name":"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=","datePublished":"2023-01-30T13:22:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODcxNCM1Mzc4ODA5IzIyMDQ4MDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaccitech-appoints-industry-veteran-nadege-pelletier-ph-d-as-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaccitech Appoints Industry Veteran, Nad\u00e8ge Pelletier, Ph.D., as Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726759"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726759\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}